Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336416 | PMC |
| http://dx.doi.org/10.1002/mdc3.12577 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States.
J Manag Care Spec Pharm
October 2024
Atrium Health Wake Forest Medical University, Charlotte, NC.
Background: At present, 4 prescription therapies have been approved by the US Food and Drug Administration for the treatment of chronic idiopathic constipation (CIC) in adults.
Objectives: To compare persistence with and adherence to prucalopride vs 3 other prescription medications for CIC in a US population.
Methods: This retrospective, observational cohort study used data from the IBM MarketScan Commercial Claims and Encounters and Medicare Supplemental Databases (January 2015-June 2020).
Emerging therapies for opioid-induced constipation: what can we expect?
Expert Opin Pharmacother
September 2024
Faculty of Pharmacy and Pharmaceutical Sciences Research Center (PSRC), Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Introduction: The rise in opioid use for managing chronic and oncologic pain has led to a significant increase in opioid-induced constipation (OIC) that impacts patient quality of life and pain management.
Areas Covered: In this study, emerging therapies for OIC were criticized for refining advancements and novel treatment options. Key topics included the efficacy of peripherally acting mu-opioid receptor antagonists (PAMORAs) such as methylnaltrexone, naloxegol, and naldemedine, which specifically target opioid-induced gut dysfunction.
Association between a selective 5-HT receptor agonist and incidence of major depressive disorder: emulated target trial.
Br J Psychiatry
September 2024
Department of Psychiatry, Warneford Hospital, University of Oxford, UK; and Warneford Hospital, Oxford Health NHS Foundation Trust, Oxford, UK.
Background: The serotonin 4 receptor (5-HTR) is a promising target for the treatment of depression. Highly selective 5-HTR agonists, such as prucalopride, have antidepressant-like and procognitive effects in preclinical models, but their clinical effects are not yet established.
Aims: To determine whether prucalopride (a 5-HTR agonist and licensed treatment for constipation) is associated with reduced incidence of depression in individuals with no past history of mental illness, compared with anti-constipation agents with no effect on the central nervous system.
Recommendations for the management of opioid-induced constipation - how to improve usability in clinical practice.
Expert Rev Gastroenterol Hepatol
November 2023
Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark.
Introduction: Opioid-induced constipation remains undertreated despite effective and safe treatment options exists. Previous guidelines have only been partially effective in improving management, possibly due to their complexity, and studies suggest that a simple setup of concise and behaviorally-orientated steps improves usability.
Areas Covered: This article introduces the concept of opioid-induced constipation and provides an overview of existing guidelines in this field.
Constipation in Patients With Chronic Kidney Disease.
J Neurogastroenterol Motil
October 2023
Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, MN, USA.
Constipation is a frequent symptom in patients with chronic kidney disease (CKD). This review outlines the mechanisms and management of constipation in patients with CKD from a physician's perspective. Common causes of constipation in patients with CKD include concomitant medications, low dietary fiber intake, water-restricted diet, lack of physical activity, altered gut microbiota, and reduced gastrointestinal motility.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!